U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H26N2O
Molecular Weight 322.4439
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)BENZENEACETAMIDE, (S)-

SMILES

CN([C@H](CN1CCCC1)C2=CC=CC=C2)C(=O)CC3=CC=CC=C3

InChI

InChIKey=OVZWUDZIAAHNFG-HXUWFJFHSA-N
InChI=1S/C21H26N2O/c1-22(21(24)16-18-10-4-2-5-11-18)20(17-23-14-8-9-15-23)19-12-6-3-7-13-19/h2-7,10-13,20H,8-9,14-17H2,1H3/t20-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15863335 | https://google.com/patents/WO1998049141A1

N-MPPP HYDROCHLORIDE is high-affinity κ agonist with no measured binding at μ or δ sites.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.8 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
1994-09-02
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Hartley-VAF Plus guinea pigs were killed by decapitation and the brains removed. The brains, less cerebellum, were homogenized in six volumes of 0.05 M Trizma buffer (pH 7.4) with a Virtrishear homogenizer at a control setting of 70 for three 5 s intervals. The homogenate was centrifuged at 25000g at 40C for 20 min. The pellet was resuspended in six volumes of aqueous 0.32 M sucrose and stored at -70 0C until needed. Frozen homogenate was thawed at room temperature and diluted with 0.05 M Trizma buffer (pH 7.4) to give a final dilution ratio of 1:60 (initial brain weight to total solution volume). Radioligands used were [3H]bremazocine (0.5 nM) for total ligand binding, [3H]DAMG0 (1.0 nM) for preceptor binding, [3H]DPDPE (1.0 nM) for delta- receptor binding, and [3H]U-69,593( 1.0 nM) for kapa-receptor N-MPPP was tested against bremazocine and DPDPE in duplicate at nine concentrations between 1.0 and 1000 nM, N-MPPP tested against [3H]U-69,593 in triplicate at five concentrations between 0.22 and 4.7 nM. Nonspecific binding was measured in the presence of 10 mkM naloxone
Name Type Language
BENZENEACETAMIDE, N-METHYL-N-((1S)-1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-
Preferred Name English
N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)BENZENEACETAMIDE, (S)-
Systematic Name English
BENZENEACETAMIDE, N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-, (S)-
Systematic Name English
N-METHYL-N-((1S)-1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)BENZENEACETAMIDE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID90935832
Created by admin on Mon Mar 31 23:07:42 GMT 2025 , Edited by admin on Mon Mar 31 23:07:42 GMT 2025
PRIMARY
CAS
157947-87-0
Created by admin on Mon Mar 31 23:07:42 GMT 2025 , Edited by admin on Mon Mar 31 23:07:42 GMT 2025
PRIMARY
PUBCHEM
190901
Created by admin on Mon Mar 31 23:07:42 GMT 2025 , Edited by admin on Mon Mar 31 23:07:42 GMT 2025
PRIMARY
FDA UNII
0G3RS2P5HF
Created by admin on Mon Mar 31 23:07:42 GMT 2025 , Edited by admin on Mon Mar 31 23:07:42 GMT 2025
PRIMARY